Ep. 10 - The Link Between Obesity and Chronic Disease: A Deeper Dive into SGLT2 Inhibitors

Cardiovascular Matters

In this educational podcast, Dr. Walker discusses the latest research on a new class of diabetes drugs called SGLT2 inhibitors like Jardiance. He explains how these medications work by blocking glucose reabsorption in the kidneys, causing it to be excreted in urine. While initially developed and approved for diabetes, extensive clinical trials have shown SGLT2 inhibitors provide significant benefits for heart failure, kidney disease, and weight loss. Dr. Walker reviews the evidence demonstrating their ability to reduce mortality, heart failure episodes, and progression to end-stage kidney disease. He also discusses proper hygiene practices for patients experiencing sugar in the urine. If you want to learn more about how SGLT2 inhibitors are revolutionizing treatment of diabetes and related conditions, watch this informative discussion.
Keynotes: This educational podcast discusses how the diabetes medication class called SGLT2 inhibitors such as Jardiance work by blocking glucose reabsorption in the kidneys, causing it to be excreted in urine, and reviews the extensive evidence that they provide significant benefits for heart failure, kidney disease, weight loss, and reducing mortality.
Timestamps:
0:00-4:00 Introduction and how SGLT2 inhibitors work
4:00-8:00 Benefits for heart failure
8:00-12:00 Additional benefits and approvals for kidney disease and weight loss
12:00-14:00 Hygiene considerations and reducing kidney failure risk
14:00-End Q&A and conclusions
For more information, visit:
Facebook Page: facebook.com/profile.php?id=61558432490919
www.cardio.com